Apolipoprotein A-I and Paraoxonase-1 Are Potential Blood Biomarkers for Ischemic Stroke Diagnosis

Walsh, Kyle B; Hart, Kimberly W.; Roll, Susan; Sperling, Matthew; Unruh, Dusten; Davidson, W. Sean; Lindsell, Christopher J.; Adeoye, Opeolu

doi:10.1016/j.jstrokecerebrovasdis.2016.02.027

Cited by 26 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Figure gives the schematic representation of the systematic review. After scanning through the title and abstract of each article, 37 full text studies were assessed for eligibility; out of which 18 articles from 2004 to 2017 were found relevant and were included in our systematic review. The review highlights the role of 10 single biomarkers (ApoC‐1, ApoC‐III, GFAP, RBP4, hs‐CRP, APC‐PCI, Apo‐AI, Paraoxonase‐1, BNP, S100B) and seven panels consisting of several different biomarkers for distinguishing the two stroke types.…”

Section: Resultsmentioning

confidence: 99%

Blood‐based protein biomarkers for stroke differentiation: A systematic review

Misra

Kumar

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

Computed tomography (CT) scan is the mainstay for diagnosis of stroke; but the facility of CT scan is not easily available. A blood-based biomarker approach is required to distinguish ischemic stroke (IS) from hemorrhagic stroke (HS) in pre-hospital settings.To conduct a systematic review of diagnostic utility of blood biomarkers for differential diagnosis of stroke.A comprehensive literature search was carried out till March 7, 2017 in PubMed, Cochrane, Medline, OVID, and Google Scholar databases. Methodological quality of each study was assessed using the modified Quality Assessment of Diagnostic Accuracy Studies questionnaire.Eighteen studies were identified relevant to our systematic review. Ten single biomarkers and seven panels of different biomarkers were identified which showed potential for differentiating IS and HS. Activated Protein C- Protein C Inhibitor Complex (APC-PCI) (sensitivity-96%), Glial Fibrillary Acidic Protein (GFAP) (specificity-100%) and a panel of APC-PCI & GFAP (sensitivity- 71%) and Retinol Binding Protein 4 (RBP4) & GFAP (specificity- 100%) were found to have high sensitivity and specificity for differentiating the two stroke types.Our systematic review does not recommend the use of any blood biomarker for clinical purposes yet based on the studies conducted till date.

show abstract

Section: Resultsmentioning

confidence: 99%

Blood‐based protein biomarkers for stroke differentiation: A systematic review

Misra

Kumar

et al. 2017

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…A novel quantitative proteomic technology, isobaric tagging for relative and absolute quantitation (iTRAQ), has recently become a powerful tool to characterize differentially expressed proteins and identify the biomarkers for central nervous systems disorders, particularly for stroke [3–5]. The new technology allows broad protein biomarker screenings, offering the hope to better understand the pathophysiological mechanisms underlying AIS due to LVO.…”

Section: Introductionmentioning

confidence: 99%

Proteomic profiling of plasma biomarkers in acute ischemic stroke due to large vessel occlusion

et al. 2019

View full text Add to dashboard Cite

Background Acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is a devastating cerebrovascular disorder, which could benefit from collateral circulation. Proteins associated with acute LVO pathogenesis and endothelial function may appear in blood samples of AIS patients due to LVO, thus permitting development of blood-based biomarkers for its diagnosis and prognosis. Methods This study is a single-center, retrospective, observational case–control trial. Consecutive patients who presented at the Department of Neurology of Tongji Hospital were recruited from July 2016 to April 2018. In the discovery phase, a proteomic approach with iTRAQ-based LC–MS/MS was used to investigate the altered proteomic pattern in plasma from patients with AIS due to LVO. In the validation study, Western blots was used to identify biomarkers associated with stroke diagnosis as well as their prognostic value associated with different collateral statuses. Results For this exploratory study, the proteomic analysis of plasma from 40 patients with AIS due to LVO and 20 healthy controls revealed seven differentially expressed proteins with a 1.2/0.83-fold or greater difference between groups. The four elevated proteins, PPBP (1.58 ± 0.78 vs 0.98 ± 0.37; P < 0.001), THBS1 (1.13 ± 0.88 vs 0.43 ± 0.26; P < 0.001), LYVE1 (1.61 ± 0.55 vs 0.97 ± 0.50; P < 0.001), and IGF2 (1.19 ± 0.42 vs 0.86 ± 0.24; P < 0.001), were verified by Western blots analysis in an independent cohort including 33 patients and 33 controls. A strong interaction was observed between the four-protein panel and the diagnosis of AIS due to LVO (AUC 0.947; P < 0.001). Furthermore, IGF2, LYVE1, and THBS1 were closely associated with collateral status (IGF2 0.115, 95% CI 0.016–0.841, P = 0.033; LYVE1 0.183, 95% CI 0.036–0.918, P = 0.039; THBS1 4.257, 95% CI 1.273–14.228, P = 0.019), and proved to be independent predictors of good outcome (IGF2 0.115, 95% CI 0.015–0.866, P = 0.036; LYVE1 0.028, 95% CI 0.002–0.334, P = 0.005; THBS1 3.294, 95% CI 1.158–9.372, P = 0.025) at a 3-month follow-up. Conclusions The identified 4-biomarker panel could provide diagnostic aid to the existing imaging modalities for AIS due to LVO, and the prognostic value of IGF2, LYVE1, and THBS1 was proved in predicting functional outcomes related to collateral status. Trial registration ClinicalTrials.gov NCT 03122002. Retrospectively registered April 20, 2017. URL of trial registry record: https://www.clinicaltrials.gov/ct2/show/NCT03122002?term=NCT+03122002&rank=1 Electronic supplementary material The online version of this article (10.1186/s12967-019-1962-8) contains supplementary material, which is available to authorized users.

show abstract

“…79 This conclusion is supported by a clinical study where ApoA-I levels were lower in ischemic stroke cases vs controls. 80 ApoB, which constitutes the gross majority of Apos found in LDL, is considered atheroprone, as reported in a meta-analysis, 79 although no significant correlation with major cardiovascular events was found in a large cohort study. 81 The existence of two allele proteins (ApoB100 and ApoB48), might bias these findings, and no report of specific determination of ApoB100 related to carotid atherosclerosis has been published as yet.…”

Section: Biomarker Descriptionsmentioning

confidence: 98%

Review of serum biomarkers in carotid atherosclerosis

Martinez

Martorell

Riambau

2020

Journal of Vascular Surgery

View full text Add to dashboard Cite

Background: Carotid artery atherosclerotic stenosis is a preventable major cause of stroke, but there is still a need for definition of high-risk plaque in asymptomatic patients who might benefit from interventional therapies. Several image markers are recommended to characterize unstable plaques. The measurement of serum biomarkers is a promising method to assist in decision making, but the lack of robust evidence in the carotid environment burdens their potential as a standard of care. The goal of this review was to offer an updated state-of-the-art study of available serum biomarkers with clinical implications, with focus on those that may predict carotid symptom development. Methods: The Cochrane Library and MEDLINE databases were searched (all until September 2018) for studies on carotid plaque and serum biomarkers of atherosclerosis. Nonhuman, basic science, and histology studies were excluded, focusing on clinical studies. Selected abstracts were screened to include the most relevant articles on atherosclerotic plaque presence, progression, instability or symptom development. Results: Some well-established biomarkers for coronary disease are not relevant to carotid atherosclerosis and other inflammatory biomarkers, lipids, interleukins, homocysteine, and adipokines may be useful in quantifying carotid disease-related risk. Some serum biomarkers combined with image features may assist vascular specialists in selecting patients at high risk for stroke and in need of intervention. Conclusions: Prospective studies applying a combination of biomarkers are essential to prove clinical usefulness.

show abstract

Apolipoprotein A-I and Paraoxonase-1 Are Potential Blood Biomarkers for Ischemic Stroke Diagnosis

Cited by 26 publications

References 32 publications

Blood‐based protein biomarkers for stroke differentiation: A systematic review

Blood‐based protein biomarkers for stroke differentiation: A systematic review

Proteomic profiling of plasma biomarkers in acute ischemic stroke due to large vessel occlusion

Review of serum biomarkers in carotid atherosclerosis

Contact Info

Product

Resources

About